毛兰素通过CCL2-CCR2信号轴介导的免疫逃避抑制食管癌细胞的恶性进展

doi:10.3969/j.issn.1006-6233.2023.10.001

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (3532 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the impact and mechanism of erianin on the malignant progression of esophageal cancer (EC) cells. Methods: The cancer tissues and adjacent tissues 3cm away from the cancer tissues of EC patients (40cases) who underwent radical surgery in our hospital from March 2021 to December 2022 were collected. Real-time fluorescence quantitative PCR (qRT-PCR) and western blot were applied to detect the mRNA and protein expression levels of CCL2 and CCR2 in EC tissues/cells, respectively; ECA109 cells were treated with different concentrations of erianin (0, 10, 20, 40, 60, 80, 160 nmoL/L) for 48 h, and cell proliferation was detected by MTT assay to screen the optimal intervention concentration. ECA109 cells were divided into control group (normal culture), low, medium and high dose erianin groups (20,40,60nmol/L), pcDNA group (transfected with pcDNA3.1), and pcDNA-CCL2 group (transfected with pcDNA3.1-CCL2), MTT assay, plate cloning assay, transwell chamber and flow cytometry were applied to detect cell proliferation, migration, invasion and apoptosis, respectively; after co-culturing ECA109 cells and CD8⁺T cells, they were grouped into T cell group, co-culture group, erianin group, pcDNA group, and pcDNA-CCL2 group. MTT and flow cytometry were applied to detect CD8⁺T cell proliferation and apoptosis, enzyme-linked immunosorbent assay (ELISA) was applied to detect the levels of interferon-γ (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α) in the supernatant of CD8⁺T cells; Western blot was applied to detect the expression of proliferating cell nuclear antigen (PCNA), Bcl-2 associated protein (Bax), programmed death ligand 1 (PD-L1), and CCL2-CCR2 signaling pathway protein in cells. Results: The expression levels of CCL2, CCR2 proteins, and mRNAs increased in EC tissues and EC cells (P<0.05); compared with the control group, the OD₄₉₀ value, colony formation number, migration and invasion cell numbers, CCL2, CCR2 mRNA, PCNA, PD-L1, CCL2, and CCR2 protein expression levels in ECA109 cells in the low, medium, and high dose erianin groups were obviously reduced, the apoptosis rate and Bax protein expression level were obviously increased (P<0.05); compared with the pcDNA group, the changes in the above indicators of ECA109 cells in the pcDNA-CCL2 group were obviously reversed (P<0.05); compared with the T cell group, the OD₄₉₀ value, IFN-γ, IL-2, and TNF-α levels of CD8⁺T cells in the co-culture group decreased, while the cell apoptosis rate increased (P<0.05); compared with the co-culture group, the OD₄₉₀ value, IFN-γ, IL-2, and TNF-α levels of CD8⁺T cells in the erianin group increased, while the cell apoptosis rate decreased (P<0.05); compared with the pcDNA group, the changes in the above indicators of CD8⁺T cells in the pcDNA-CCL2 group were obviously reversed (P<0.05). Conclusion: Erianin may inhibit the malignant progression of EC cells by inhibiting the CCL2-CCR2 signaling pathway.

Key words： Erianin CCL2-CCR2 signal axis Immune escape Esophageal cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jing
	YUAN Zhaolin
	LI Wei

Cite this article:

WANG Jing,YUAN Zhaolin,LI Wei. Erianin Inhibits the Malignant Progression of Esophageal Cancer Cells through CCL2-CCR2 Signaling Axis-Mediated Immune Evasion[J]. HeBei Med, 2023, 29(10): 1585-1593.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.10.001 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I10/1585

[1] Uhlenhopp DJ,Then EO,Sunkara T,et al.Epidemiology of esophageal cancer:update in global trends,etiology and risk factors[J].Clin Gastroenterol,2020,13(6):1010-1021.
[2] Yan L,Zhang Z,Liu Y,et al.Anticancer activity of erianin:cancer-specific target prediction based on network pharmacology[J].Front Mol Biosci,2022,9(1):1-17.
[3] 洪静,杨方瑶,蒋立翔,等.天然产物活性分子毛兰素抗肿瘤作用研究进展[J].生物学杂志,2022,39(6):89-93.
[4] Hao Q,Vadgama JV,Wang P.CCL2/CCR2 signaling in cancer pathogenesis[J].Cell Commun Signal,2020,18(1):82-94.
[5] Yang H,Zhang Q,Xu M,et al.CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis[J].Mol Cancer,2020,19(1):41-54.
[6] Xu Y,Fang R,Shao J,et al.Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway[J].Biosci Rep,2021,41(6):1-9.
[7] Xiang Y,Chen X,Wang W,et al.Natural product erianin inhibits bladder cancer cell growth by inducing ferroptosis via NRF2 inactivation[J].Front Pharmacol,2021,12(1):1-9.
[8] Shen H,Geng Z,Nie X,et al.Erianin induces ferroptosis of renal cancer stem cells via promoting ALOX12/P53 mRNA N6-methyladenosine modification[J].Cancer,2023,14(3):367-378.
[9] Zhu Q,Sheng Y,Li W,et al.Erianin,a novel dibenzyl compound in dendrobium extract,inhibits bladder cancer cell growth via the mitochondrial apoptosis and JNK pathways[J].Toxicol Appl Pharmacol,2019,371(1):41-54.
[10] Zhang X,Wang Y,Li X,et al.The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer[J].Aging (Albany NY),2019,1(22):10284-10300.
[11] Sun Y,Li G,Zhou Q,et al.Dual targeting of cell growth and phagocytosis by erianin for human colorectal cancer[J].Drug Des Devel Ther,2020,14(1):3301-3313.
[12] Zhang HQ,Xie XF,Li GM,et al.Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo[J].Phytother Res,2021,35(8):4511-4525.